Vanguard Asset Management
CMPX icon

Vanguard Asset Management’s Compass Therapeutics CMPX Stock Holding History

Vanguard Asset Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$164K Hold
74,689
– – ﹤0.01% 2391
2026
Q1 		$395K Buy
+74,689
New +$431K ﹤0.01% 2204

Other funds holding CMPX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Asset Management's CMPX Position: Q2 2026 in Review

Vanguard Asset Management held its Compass Therapeutics (CMPX) position steady in Q2 2026 at 74,689 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #2391.

Vanguard Asset Management first reported a position in CMPX in Q1 2026 and has held it in 2 quarters since. The position peaked at $395K in Q1 2026. 197 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Vanguard Asset Management held 74,689 shares of Compass Therapeutics worth $164K as of Q2 2026.
  • Vanguard Asset Management left its Compass Therapeutics share count unchanged in Q2 2026.
  • Compass Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2391 holding.
  • Vanguard Asset Management first reported a position in Compass Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Asset Management's Compass Therapeutics position peaked at $395K in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.